Original ResearchClinical—LiverEfficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients With Chronic Hepatitis B
Section snippets
Study Design
This was a randomized, open-label, multicenter, phase 3b superiority study (ETV-110, the BE-LOW study; NCT00410072) in NA-naïve HBeAg-positive or HBeAg-negative patients with CHB. Patients were randomized 1:1 to receive ETV 0.5 mg plus TDF 300 mg once daily or ETV 0.5 mg once daily for 100 weeks, with the primary end point measurement at week 96. To test whether patients with high viral load might derive greater benefit from combination therapy, the total number of HBeAg-negative patients was
Patient Population
Of the 384 patients randomized in this study, 379 were treated with ETV plus TDF (n = 197) or ETV alone (n = 182) (Figure 1 and Supplementary Figure 1). More patients in the combination arm than in the monotherapy arm discontinued therapy before week 96 (23 [11.6%] vs 12 [6.5%]), but this difference was not statistically significant (P = .11). The most common reasons for treatment discontinuation were lost to follow-up (ETV + TDF, 6; ETV, 7) and adverse events (ETV + TDF, 5; ETV, 2). At the end
Discussion
In this study, which included a mixed population of NA-naïve HBeAg-positive and HBeAg-negative patients with compensated CHB, the antiviral efficacy of ETV monotherapy was comparable to that of ETV plus TDF. At week 96, combined treatment with ETV plus TDF did not result in a higher proportion of patients with an HBV DNA level <50 IU/mL, ALT normalization, HBeAg loss, or HBeAg seroconversion compared with ETV monotherapy. When the responses of HBeAg-positive and HBeAg-negative patients were
Acknowledgments
In addition to the authors, the BE-LOW Study Group consists of the following principal investigators: Frank Anderson (Canada), Peter Angus (Australia), Giorgio Antonucci (Italy), David Bernstein (United States), Fernardo Bessone (Argentina), Marc Bourliere (France), Maurizia R. Brunetto (Italy), Olivier Chazouilleres (France), Sing Chan (United States), Hugo Cheinquer (Brazil), Gourdas Choudhuri (India), Douglas Dieterich (United States), Paul Desmond (Australia), Chundamannil Eapen (India),
References (36)
- et al.
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B
J Hepatol
(2008) - et al.
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B
Gastroenterology
(2005) - et al.
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B
Gastroenterology
(2007) - et al.
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
Gastroenterology
(2011) - et al.
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B
J Hepatol
(2011) - et al.
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach
Gastroenterology
(2008) - et al.
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
J Hepatol
(2009) - et al.
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation
J Hepatol
(2005) - et al.
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy
Hepatology
(2001) - et al.
Continued virologic and biochemical improvement through 96 weeks of entecavir treatment In HBeAg(-) chronic hepatitis B patients (study ETV-027)
Hepatology
(2006)
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
Hepatology
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
Gastroenterology
EASL Clinical Practice Guidelines: management of chronic hepatitis B
J Hepatol
Chronic hepatitis B: update 2009
Hepatology
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management
Hepatology
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
JAMA
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses
Gastroenterology
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
Hepatology
Cited by (135)
Managing HBV and HCV Infection Pre- and Post-liver Transplant
2024, Journal of Clinical and Experimental HepatologyAsociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B
2021, Revista de Gastroenterologia de MexicoTenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen–Positive Chronic Hepatitis B
2021, Journal of Clinical and Experimental HepatologyCitation Excerpt :A total of 250 CHB cases treated either with TDF (n = 140) or ETV (n = 110) for at least 24 months were screened for the study and evaluated. All patients with CHB of age more than 18 years, hepatitis B surface antigen (HBsAg) seropositivity for more than 6 months and pretreatment serum HBV-DNA level > 2 x 105 IU/ml and ALT > 2 x ULN in HBeAg seropositive cases; HBV DNA > 2 x 104 IU/ml and ALT > 2 x ULN in case of HBeAg-negative cases (as per AASLD guidelines (6)) with compensated liver function as defined by serum total bilirubin level ≤2.5 mg/dL, serum albumin level ≥3 g/dL and international normalized ratio ≤1.5 were included in the study.8 Those cases who were previously treated with nucleos(t)ide or IFN, patients with decompensated cirrhosis, history of coinfection with hepatitis C, D or HIV, having history of any other liver disease such as alcoholic liver disease, nonalcoholic fatty liver disease or autoimmune liver disease, HCC, patients with incomplete treatment record and nonadherence to treatment were excluded from the study.
Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis
2020, Hepatobiliary and Pancreatic Diseases InternationalNo Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir
2020, Clinical Gastroenterology and Hepatology
Editorial support was provided by Articulate Science and funded by Bristol-Myers Squibb.
Conflicts of interest The authors disclose the following: Anna S. Lok has received research grants from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Roche, and Merck and has served as ad hoc advisor for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, and Roche. Ulus S. Akarca is an advisory board member of Bristol-Myers Squibb, Gilead, and MSD and a consultant for Gilead. Adrian Gadano has provided consultancy services for Bristol-Myers Squibb. François Habersetzer has received lecture fees, consulting fees, and investigator fees from Bristol-Myers Squibb and Gilead. William Sievert is a member of Australian Advisory Boards for Bristol-Myers Squibb and Gilead. Meghan Lovegren, David Cohen, and Cyril Llamoso are employees of Bristol-Myers Squibb. The remaining authors disclose no conflicts.
Funding Supported by Bristol-Myers Squibb.